Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options

Diffuse large B-cell lymphoma (DLBCL) represents a curable disease with a 60–70% chance of cure with current R-CHOP chemoimmunotherapy. However, 30–40% of patients are refractory or relapsing. Many attempts failed to improve the outcome of DLBCL patients, including the intensification of R-CHOP regi...

Descripción completa

Detalles Bibliográficos
Autores principales: Vodicka, Prokop, Klener, Pavel, Trneny, Marek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739046/
https://www.ncbi.nlm.nih.gov/pubmed/36510607
http://dx.doi.org/10.2147/OTT.S326632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739046/
https://www.ncbi.nlm.nih.gov/pubmed/36510607
http://dx.doi.org/10.2147/OTT.S326632

Ejemplares similares